Literature DB >> 21602034

Negative symptoms and psychosocial functioning in schizophrenia: neglected but important targets for treatment.

R Hunter1, S Barry.   

Abstract

BACKGROUND: Many patients with schizophrenia suffer from poor social functioning, with high levels of unemployment being one particular consequence. Negative symptoms tend to persist during periods of clinical stability and may have a detrimental effect on function. This paper aims to investigate the relationship between negative symptoms and ability to function.
METHODS: The EGOFORS study measured negative symptoms in 295 schizophrenia patients in 11 European sites using the PANSS Negative Subscale and assessment scales for psychosocial function: Global Assessment of Functioning (GAF), Personal and Social Performance (PSP), Quality of Life Scale (QLS), Functional Remission of General Schizophrenia (FROGS), Psychosocial Remission in Schizophrenia (PSRS) and Subjective Wellbeing under Neuroleptics (SWN). The relationships between the PANSS Negative Subscale and the functional scales were investigated, adjusting for differences between study sites. Being in work, duration of illness, age of onset and number of years of education were also investigated for a relationship with function.
RESULTS: There were strong, statistically significant correlations between PANSS Negative Subscale and all of the function scales (95% confidence intervals for the correlation coefficients: PSRS 0.77-0.91; FROGS 0.74-0.89; QLS 0.74-0.92; GAF 0.64-0.78; PSP 0.63-0.80) except the SWN. All of the functional scales except SWN were at least moderately related to one another. All of the items in each of the PANSS Negative Subscale and the function scales contributed to the relationships between them. Better functioning correlated strongly with participants being in work.
CONCLUSION: This study shows a strong and significant relationship between negative symptoms and psychosocial functioning. Given the impact of negative symptoms on psychosocial function, much more emphasis should be placed on developing effective treatments for negative symptoms, given that most patients with schizophrenia now live in community settings and require to function adequately to support their quality of life.
Copyright © 2011 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21602034     DOI: 10.1016/j.eurpsy.2011.02.015

Source DB:  PubMed          Journal:  Eur Psychiatry        ISSN: 0924-9338            Impact factor:   5.361


  33 in total

1.  Emotional granularity and social functioning in individuals with schizophrenia: an experience sampling study.

Authors:  David Kimhy; Julia Vakhrusheva; Samira Khan; Rachel W Chang; Marie C Hansen; Jacob S Ballon; Dolores Malaspina; James J Gross
Journal:  J Psychiatr Res       Date:  2014-02-11       Impact factor: 4.791

2.  Assessing Social Affiliative Behavior: A Comparison of in Vivo and Video Tasks.

Authors:  Cristina P Garcia; Lauren T Catalano; Kristen R Dwyer; Julie M McCarthy; Melanie E Bennett; Jack J Blanchard
Journal:  Behav Ther       Date:  2018-03-19

3.  Clozapine and Psychosocial Function in Schizophrenia: A Systematic Review and Meta-Analysis.

Authors:  Andrew T Olagunju; Scott R Clark; Bernhard T Baune
Journal:  CNS Drugs       Date:  2018-11       Impact factor: 5.749

4.  The association of psychopathology with concurrent level of functioning and subjective well-being in persons with schizophrenia spectrum disorders.

Authors:  Lisa Hochstrasser; Stefan Borgwardt; Martin Lambert; Benno G Schimmelmann; Undine E Lang; Rolf-Dieter Stieglitz; Christian G Huber
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2017-03-29       Impact factor: 5.270

5.  Systematic review of global functioning and quality of life in people with psychotic disorders.

Authors:  A G Nevarez-Flores; K Sanderson; M Breslin; V J Carr; V A Morgan; A L Neil
Journal:  Epidemiol Psychiatr Sci       Date:  2018-10-01       Impact factor: 6.892

6.  Emotion awareness and regulation in individuals with schizophrenia: Implications for social functioning.

Authors:  David Kimhy; Julia Vakhrusheva; Lauren Jobson-Ahmed; Nicholas Tarrier; Dolores Malaspina; James J Gross
Journal:  Psychiatry Res       Date:  2012-06-30       Impact factor: 3.222

7.  A comprehensive model of predictors of quality of life in older adults with schizophrenia: results from the CSA study.

Authors:  Nicolas Hoertel; Léa Rotenberg; Carlos Blanco; Vincent Camus; Caroline Dubertret; Véronique Charlot; Franck Schürhoff; Pierre Vandel; Frédéric Limosin
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2020-05-15       Impact factor: 4.328

8.  The impact of gender on treatment effectiveness of body psychotherapy for negative symptoms of schizophrenia: A secondary analysis of the NESS trial data.

Authors:  Mark Savill; Stavros Orfanos; Richard Bentall; Ulrich Reininghaus; Til Wykes; Stefan Priebe
Journal:  Psychiatry Res       Date:  2016-11-14       Impact factor: 3.222

Review 9.  Cariprazine, A Broad-Spectrum Antipsychotic for the Treatment of Schizophrenia: Pharmacology, Efficacy, and Safety.

Authors:  István Laszlovszky; Ágota Barabássy; György Németh
Journal:  Adv Ther       Date:  2021-06-06       Impact factor: 3.845

10.  Negative symptoms in schizophrenia: a study in a large clinical sample of patients using a novel automated method.

Authors:  Rashmi Patel; Nishamali Jayatilleke; Matthew Broadbent; Chin-Kuo Chang; Nadia Foskett; Genevieve Gorrell; Richard D Hayes; Richard Jackson; Caroline Johnston; Hitesh Shetty; Angus Roberts; Philip McGuire; Robert Stewart
Journal:  BMJ Open       Date:  2015-09-07       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.